Literature DB >> 4368469

Canrenoate in normal man.

W J Mroczek, M E Davidov, A Horoschak, F A Finnerty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4368469     DOI： 10.1002/cpt1974162336

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

1.  Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

Authors:  Maysa Suyagh; Ahmed F Hawwa; Paul S Collier; Jeffrey S Millership; Prashant Kole; Muriel Millar; Mike D Shields; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Canrenone--the principal active metabolite of spironolactone?

Authors:  L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

4.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.